Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study

被引：1

作者：

Gavriatopoulou, Maria ^{[1
]}

Vogl, Dan T. ^{[2
]}

Nooka, Ajay ^{[3
]}

Dingli, David ^{[4
]}

Cole, Craig ^{[5
]}

Moreau, Philippe ^{[6
]}

Huff, Carol ^{[7
]}

Yee, Andrew ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

Lonial, Sagar ^{[10
]}

Richardson, Paul G. ^{[11
]}

Stewart, Keith ^{[12
]}

Chari, Ajai ^{[13
]}

Richter, Joshua ^{[14
]}

Biran, Noa ^{[14
]}

Siegel, David S. ^{[15
]}

Liu, Jianjun ^{[16
]}

Joshi, Anita ^{[16
]}

Shah, Jatin ^{[16
]}

Shacham, Sharon ^{[16
]}

Kauffman, Michael ^{[16
]}

Jagannath, Sundar ^{[17
]}

机构：

[1] Univ Athens, Sch Med, Athens, Greece

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] Mayo Clin, Rochester, MN USA

[5] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[6] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France

[7] Johns Hopkins Univ, Baltimore, MD USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[9] Univ Athens, Sch Med, Alexandra Hosp, Athens, Greece

[10] Emory Univ, Atlanta, GA 30322 USA

[11] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[12] Mayo Clin, Scottsdale, AZ USA

[13] Mt Sinai Sch Med, New York, NY USA

[14] Hackensack Univ, John Theurer Canc Ctr, Hackensack, NJ USA

[15] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[16] Karyopharm Therapeut Inc, Newton, MA USA

[17] Mt Sinai Hosp, New York, NY 10029 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Elderly patients; novel agents; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.195

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FP-110

引用

页码：E117 / E118

页数：2

共 50 条

[41] Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
Tomer, Mark
Lucio, Gordan
David, Ray
Stephen, Ijioma
George, Dranitsaris
Amanda, Warner
Trevor, Heritage
Matthew, Fink
David, Wenk
Shachar, Peles
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S24 - S24
[42] Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
White, Darrell J.
LeBlanc, Richard
Baljevic, Muhamed
Bahlis, Nizar J.
Lentzsch, Suzanne
Venner, Christopher P.
Gasparetto, Cristina
Chen, Christine I.
Lipe, Brea
Tuchman, Sascha A.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
Callander, Natalie S.
Bensinger, William I.
Rossi, Adriana C.
Sheehan, Heidi
Van Domelen, Dane
Zhou, Tianjun
Kazuharu, Kai
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Schiller, Gary J.
BLOOD, 2020, 136
[43] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Richardson, Paul
Jagannath, Sundar
Hussein, Mohamad
Berenson, James
Singhal, Seema
Irwin, David
Williams, Stephanie F.
Bensinger, William
Badros, Ashraf Z.
Vescio, Robert
Kenvin, Laurie
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert
Anderson, Kenneth C.
BLOOD, 2009, 114 (04) : 772 - 778
[44] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Berenson, James R.
Silagan, Noemi
To, Jennifer
Spektor, Tanya M.
Martinez, Daisy
Sanchez, Armando J.
Forouzan, Eli
Swift, Regina
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Boccia, Ralph V.
Yang, Honghao Hank
Lim, Stephen
Vescio, Robert
BLOOD, 2020, 136
[45] Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease: a post-hoc analysis of the ODYSSEY programme
Colhoun, H.
Valcheva, V.
Guillonneau, S.
Wang, H.
Sanchez, R. J.
Ray, K. K.
DIABETOLOGIA, 2016, 59 : S529 - S530
[46] Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
White, Darrell
Schiller, Gary J.
Madan, Sumit
Lentzsch, Suzanne
Chubar, Evgeni
Lavi, Noa
Van Domelen, Dane R.
Bentur, Ohad S.
Baljevic, Muhamed
FRONTIERS IN ONCOLOGY, 2024, 14
[47] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
Raje, Noopur
Leleu, Xavier
Lesokhin, Alexander
Mohty, Mohamad
Nooka, Ajay K.
Leip, Eric
Conte, Umberto
Viqueira, Andrea
Manier, Salomon
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
[48] EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Canovas, A.
Alonso, J. J.
Barreiro, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 625 - 625
[49] Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Schuster, Michael
Zijlstra, Josee
Casasnovas, Rene-Olivier
Vermaat, Joost S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van Den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Follows, George
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel
Maerevoet, Marie
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 483 - 494
[50] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sanchez, R. Garcia
Saldana, R.
Caparros, I.
Gallardo, A.
Garcia-Delgado, R.
Rosell, A.
Campos, A.
de Llano, M. P. Queipo
Perez, I.
Moreno, M. J.
Del Castillo, S.
De la Torre, S.
Ramirez, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500

← 1 2 3 4 5 →